VIE Manufacturing Science & Technology Lab Associate Scientist
UCB Pharma
VIE Manufacturing Science & Technology Lab Associate Scientist
UCB Pharma
Biopharmaceuticals for neurology and immunology therapies
Make your mark for patients
UCB is an international biopharmaceutical company primarily engaged in the research, development, and commercialization of pharmaceutical and biotechnological products. It specializes in researching therapeutic solutions for patients suffering from severe diseases, treated by specialists, particularly in the fields of the central nervous system (including epilepsy) and inflammation (including allergies).
The Braine-l'Alleud site specializes in chemical synthesis, development, manufacturing, and packaging of pharmaceutical products.
More information at: www.ucb.com
We are looking for a dynamic and collaborative Manufacturing Science & Technology (MSAT) Laboratory Associate Scientist to join our global Biologics MSAT team based at UCB’s campus in Braine-l’Alleud, Belgium.
In this role, you will perform laboratory work to support process development activities and address the needs of commercial manufacturing groups worldwide. You will also build strong technical and scientific partnerships with process development, manufacturing, and external partner organizations, acting as a laboratory expert in downstream processing (DSP).
The MSAT Laboratory Associate Scientist will play a key role in:
Your Profile:
Please note that this program is in partnership with Business France, and we follow the prerequisites required by Business France to carry out a VIE assignment. The main participation prerequisites are as follows:
If you do not meet all these conditions, we will not be able to consider your application.
Biopharmaceuticals for neurology and immunology therapies
UCB Pharma focuses on developing treatments for severe diseases in neurology and immunology. It discovers, develops, and commercializes novel molecules and generates products aimed at improving patient lives. The company works by researching and developing therapies, integrating patient insights to guide innovation, and investing over a quarter of revenue into scientific research. Its global presence (about 9,000 employees across 40 countries) and €5.3 billion 2023 revenue reflect its scale and commitment to bringing therapies to patients worldwide. UCB differentiates itself by combining direct patient engagement with substantial R&D investment to address unmet needs in neurology and immunology, aiming to transform lives through science and patient care.
Explore more opportunities at UCB Pharma